GRAIL (NASDAQ:GRAL) Sees Unusually-High Trading Volume – Should You Buy?

Shares of GRAIL, Inc. (NASDAQ:GRAL) saw unusually-high trading volume on Monday . Approximately 1,291,529 shares were traded during trading, an increase of 6% from the previous session’s volume of 1,220,625 shares.The stock last traded at $43.9680 and had previously closed at $50.21.

Analyst Ratings Changes

A number of brokerages have commented on GRAL. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Robert W. Baird set a $82.00 target price on GRAIL in a research report on Friday. Morgan Stanley boosted their price objective on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Guggenheim increased their price objective on shares of GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, TD Cowen initiated coverage on shares of GRAIL in a report on Thursday. They issued a “hold” rating and a $114.00 price target for the company. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and an average target price of $98.50.

GRAIL Stock Down 15.0%

The stock’s 50 day moving average price is $96.61 and its two-hundred day moving average price is $76.53. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -3.83 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.33) by $0.89. The business had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. On average, equities analysts expect that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Institutional Trading of GRAIL

Several large investors have recently modified their holdings of GRAL. N.E.W. Advisory Services LLC acquired a new stake in shares of GRAIL in the fourth quarter valued at about $26,000. Elyxium Wealth LLC bought a new position in GRAIL during the fourth quarter worth $31,000. Comerica Bank boosted its holdings in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Intesa Sanpaolo S.p.A. bought a new position in shares of GRAIL during the 4th quarter worth about $44,000. Finally, Ankerstar Wealth LLC acquired a new position in shares of GRAIL during the fourth quarter valued at about $45,000.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.